Who are FOLFOXIRI with bevacizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FOLFOX/ FOLFIRI with bevacizumab, Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab, carboplatin paclitaxel bevacizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folfoxiri-with-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

FOLFOXIRI with bevacizumab — Competitive Intelligence Brief

FOLFOXIRI with bevacizumab (FOLFOXIRI with bevacizumab) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination with anti-angiogenic monoclonal antibody. Area: Oncology.

phase 3 Chemotherapy combination with anti-angiogenic monoclonal antibody VEGF (bevacizumab component); topoisomerase I, thymidylate synthase, DNA (FOLFOXIRI components) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

FOLFOXIRI with bevacizumab (FOLFOXIRI with bevacizumab) — Dutch Colorectal Cancer Group. FOLFOXIRI with bevacizumab combines three chemotherapy drugs (fluorouracil, oxaliplatin, and irinotecan) with an anti-angiogenic monoclonal antibody to kill colorectal cancer cells and block tumor blood vessel formation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FOLFOXIRI with bevacizumab TARGET	FOLFOXIRI with bevacizumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	VEGF (bevacizumab component); topoisomerase I, thymidylate synthase, DNA (FOLFOXIRI components)
FOLFOX/ FOLFIRI with bevacizumab	FOLFOX/ FOLFIRI with bevacizumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (chemotherapy); VEGF (bevacizumab)
Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab	Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab	Lee's Pharmaceutical Limited	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (platinum agents), microtubules (paclitaxel), VEGF (bevacizumab)
carboplatin paclitaxel bevacizumab	carboplatin paclitaxel bevacizumab	Gruppo Oncologico Italia Meridionale	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (carboplatin), microtubules (paclitaxel), VEGF (bevacizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination with anti-angiogenic monoclonal antibody class)

Dutch Colorectal Cancer Group · 2 drugs in this class
Gruppo Oncologico Italia Meridionale · 1 drug in this class
Lee's Pharmaceutical Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FOLFOXIRI with bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/folfoxiri-with-bevacizumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab